SCHEMBL5137486

SCHEMBL5137486

CCCCn1c(CN(CCc2ccccc2OCC)Cc2ccc3c(c2)OCO3)cnc1-c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.52
POLB P06746 2/20 0.52
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
KDM4E B2RXH2 1/20 0.49
TSHR P16473 1/20 0.49
C5AR1 P21730 1/20 0.46
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTR2A P28223 4/20 0.40
HTR2C P28335 4/20 0.40
HTR2B P41595 4/20 0.40
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135001 0.95 TP53 (0.54) TP53POLBMEN1KMT2AKDM4E
SCHEMBL5136199 0.94 HTR2A (0.47) TP53POLBMEN1KMT2AKDM4E
SCHEMBL5136307 0.92 C5AR1 (0.46) TP53POLBMEN1KMT2AKDM4E
SCHEMBL5150126 0.92 C5AR1 (0.47) TP53POLBMEN1KMT2AKDM4E
SCHEMBL5135806 0.90 C5AR1 (0.46) TP53POLBMEN1KMT2AKDM4E
SCHEMBL5136702 0.90 C5AR1 (0.51) TP53POLBMEN1KMT2AKDM4E
SCHEMBL5136744 0.90 C5AR1 (0.47) TP53POLBMEN1KMT2AKDM4E
SCHEMBL5137303 0.89 TP53 (0.51) TP53POLBMEN1KMT2AKDM4E
SCHEMBL5149996 0.88 C5AR1 (0.49) TP53POLBKDM4EC5AR1SMN1; SMN2
SCHEMBL5135206 0.88 TP53 (0.45) TP53POLBC5AR1SMN1; SMN2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed